A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo
A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
Inclusion criteria:
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria applied
Tucson, Arizona 85719, United States
Los Angeles, California 90095, United States
Norwich, Connecticut 06360, United States
Kansas City, Kansas 66160, United States
New Orleans, Louisiana 70112, United States
St Louis, Missouri 63110, United States
Albany, New York 12206, United States
Durham, North Carolina 27710, United States
Corpus Christi, Texas 78405, United States
Houston, Texas 77030, United States
Madison, Wisconsin 53792, United States
Clichy Cédex, 92118, France